Wilkins MR - Search Results

1

Rhodes CJ, Wharton J, Wilkins MR. Rhodes CJ, et al. Among authors: wilkins mr. Handb Exp Pharmacol. 2013;218:77-103. doi: 10.1007/978-3-642-38664-0_4. Handb Exp Pharmacol. 2013. PMID: 24092337 Review.

2

Recent insights into the pathogenesis and therapeutics of pulmonary hypertension.

Strange JW, Wharton J, Phillips PG, Wilkins MR. Strange JW, et al. Among authors: wilkins mr. Clin Sci (Lond). 2002 Mar;102(3):253-68. Clin Sci (Lond). 2002. PMID: 11869166 Review.

3

Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity.

Zhao L, Mason NA, Strange JW, Walker H, Wilkins MR. Zhao L, et al. Among authors: wilkins mr. Circulation. 2003 Jan 21;107(2):234-7. doi: 10.1161/01.cir.0000050653.10758.6b. Circulation. 2003. PMID: 12538421

4

Pulmonary arterial hypertension and the vasoconstrictive factor: is there still a role for vasodilator testing?

Gibbs JS, Wharton J, Wilkins MR. Gibbs JS, et al. Among authors: wilkins mr. Eur Heart J. 2003 Feb;24(4):297-8. doi: 10.1016/s0195-668x(02)00753-4. Eur Heart J. 2003. PMID: 12581676 No abstract available.

5

Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension.

Sebkhi A, Strange JW, Phillips SC, Wharton J, Wilkins MR. Sebkhi A, et al. Among authors: wilkins mr. Circulation. 2003 Jul 1;107(25):3230-5. doi: 10.1161/01.CIR.0000074226.20466.B1. Epub 2003 Jun 9. Circulation. 2003. PMID: 12796132

6

Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study.

Wilkins MR, Paul GA, Strange JW, Tunariu N, Gin-Sing W, Banya WA, Westwood MA, Stefanidis A, Ng LL, Pennell DJ, Mohiaddin RH, Nihoyannopoulos P, Gibbs JS. Wilkins MR, et al. Am J Respir Crit Care Med. 2005 Jun 1;171(11):1292-7. doi: 10.1164/rccm.200410-1411OC. Epub 2005 Mar 4. Am J Respir Crit Care Med. 2005. PMID: 15750042 Clinical Trial.

7

Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells.

Wharton J, Strange JW, Møller GM, Growcott EJ, Ren X, Franklyn AP, Phillips SC, Wilkins MR. Wharton J, et al. Among authors: wilkins mr. Am J Respir Crit Care Med. 2005 Jul 1;172(1):105-13. doi: 10.1164/rccm.200411-1587OC. Epub 2005 Apr 7. Am J Respir Crit Care Med. 2005. PMID: 15817798

8

Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension.

Paul GA, Gibbs JS, Boobis AR, Abbas A, Wilkins MR. Paul GA, et al. Among authors: wilkins mr. Br J Clin Pharmacol. 2005 Jul;60(1):107-12. doi: 10.1111/j.1365-2125.2005.02383.x. Br J Clin Pharmacol. 2005. PMID: 15963102 Free PMC article.

9

Identification of plasma protein biomarkers associated with idiopathic pulmonary arterial hypertension.

Abdul-Salam VB, Paul GA, Ali JO, Gibbs SR, Rahman D, Taylor GW, Wilkins MR, Edwards RJ. Abdul-Salam VB, et al. Among authors: wilkins mr. Proteomics. 2006 Apr;6(7):2286-94. doi: 10.1002/pmic.200500510. Proteomics. 2006. PMID: 16493708

10

Emerging therapies for pulmonary arterial hypertension.

Ali O, Wharton J, Gibbs JS, Howard L, Wilkins MR. Ali O, et al. Among authors: wilkins mr. Expert Opin Investig Drugs. 2007 Jun;16(6):803-18. doi: 10.1517/13543784.16.6.803. Expert Opin Investig Drugs. 2007. PMID: 17501693 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

568 results

Search Page